Cure of murine leishmaniasis with anti-interleukin 4 monoclonal antibody. Evidence for a T cell-dependent, interferon gamma-independent mechanism.
about
UVB induces IL-12 transcription in human keratinocytes in vivo and in vitroThe effect of intravenous administration of a chimeric anti-IgE antibody on serum IgE levels in atopic subjects: efficacy, safety, and pharmacokineticsIn vivo cytokine profiles in patients with kala-azar. Marked elevation of both interleukin-10 and interferon-gammaEvidence that the T cell repertoire of normal rats contains cells with the potential to cause diabetes. Characterization of the CD4+ T cell subset that inhibits this autoimmune potentialOX-22high CD4+ T cells induce wasting disease with multiple organ pathology: prevention by the OX-22low subsetSwitch from a type 2 to a type 1 T helper cell response and cure of established Leishmania major infection in mice is induced by combined therapy with interleukin 12 and PentostamDepletion of interleukin-4 in BALB/c mice with established Leishmania major infections increases the efficacy of antimony therapy and promotes Th1-like responsesIndomethacin treatment slows disease progression and enhances a Th1 response in susceptible BALB/c mice infected with Leishmania majorSuccessful therapy of chronic, nonhealing murine cutaneous leishmaniasis with sodium stibogluconate and gamma interferon depends on continued interleukin-12 productionTherapeutic enhancement of protective immunity during experimental leishmaniasisRecombinant soluble interleukin-4 (IL-4) receptor acts as an antagonist of IL-4 in murine cutaneous LeishmaniasisLeishmania eukaryotic initiation factor (LeIF) inhibits parasite growth in murine macrophagesIL-4 attenuates Th1-associated chemokine expression and Th1 trafficking to inflamed tissues and limits pathogen clearance.IL-4 and IL-13 regulate the induction of indoleamine 2,3-dioxygenase activity and the control of Toxoplasma gondii replication in human fibroblasts activated with IFN-gamma.Deletion of IL-4Ralpha on CD4 T cells renders BALB/c mice resistant to Leishmania major infection.Alternative activation of macrophages by IL-4 impairs phagocytosis of pathogens but potentiates microbial-induced signalling and cytokine secretionImmune responses associated with susceptibility of C57BL/10 mice to Leishmania amazonensis.Interleukin-4 but not gamma interferon production correlates with the severity of murine cutaneous leishmaniasis.Gamma interferon response in secondary Leishmania major infection: role of CD8+ T cellsAn avirulent lipophosphoglycan-deficient Leishmania major clone induces CD4+ T cells which protect susceptible BALB/c mice against infection with virulent L. majorLeishmania major infection of inbred mice: unmasking genetic determinants of infectious diseases.Role of CTLA-4, IL-18 and IL-10 on the Induction of Low Dose Oral Tolerance.Some of the early events underlying Th2 cell maturation and susceptibility to Leishmania major infection in BALB/c mice.Analysis of the immune responses of mice to infection with Leishmania braziliensisCytokine involvement in immunomodulatory activity affected by Candida albicans mannan.Alterations in frequency of interleukin-2 (IL-2)-, gamma interferon-, or IL-4-secreting splenocytes induced by Candida albicans mannan and/or monophosphoryl lipid AImportance of interleukin-10 in genetic susceptibility of mice to Coccidioides immitis.The protective Th1 response in mice is induced in the T-cell zone only three weeks after infection with Leishmania major and not during early T-cell activation.Cytokine patterns in the pathogenesis of human leishmaniasis.Low-dose UVB contributes to host resistance against Leishmania amazonensis infection in mice through induction of gamma interferon and tumor necrosis factor alpha cytokines.Immunization of BALB/c mice with killed Neospora caninum tachyzoite antigen induces a type 2 immune response and exacerbates encephalitis and neurological diseaseInterleukin-4 receptor alpha-deficient BALB/c mice show an unimpaired T helper 2 polarization in response to Leishmania major infectionT cells that react to the immunodominant Leishmania major LACK antigen prevent early dissemination of the parasite in susceptible BALB/c miceRisks for infection in patients with asthma (or other atopic conditions): is asthma more than a chronic airway disease?Vaccination with the Leishmania infantum acidic ribosomal P0 protein plus CpG oligodeoxynucleotides induces protection against cutaneous leishmaniasis in C57BL/6 mice but does not prevent progressive disease in BALB/c mice.Distinct CD4+-T-cell responses to live and heat-inactivated Aspergillus fumigatus conidia.Combined treatment with interleukin-12 and indomethacin promotes increased resistance in BALB/c mice with established Leishmania major infectionsAnti-tumor necrosis factor modulates anti-CD3-triggered T cell cytokine gene expression in vivo.Anti-IL-4 treatment at immunization modulates cytokine expression, reduces illness, and increases cytotoxic T lymphocyte activity in mice challenged with respiratory syncytial virus.Induction of murine T-helper-cell responses to the filarial nematode Brugia malayi
P2860
Q24312131-E05D5E71-8DFD-4450-BDA3-157519FB62FDQ24561800-F7CFB901-D618-463E-BE68-08800C0F1C4FQ24599396-593EA9E4-D979-462E-A0D9-A4BB946C9B78Q24680634-3702357C-58F0-47AA-83BC-F303273C679DQ24682576-33946A66-8649-4E2F-B2C5-6D70D8D6EB84Q28368077-D18DB3BB-38E4-4C20-951A-1F5FB632B6CEQ28369065-65DD598C-AC03-4528-BA2A-EDC0403A81CEQ28375573-28AB43AD-322D-40AD-85BB-A721394E95FEQ28379055-E3E7C242-5DDE-4B94-86FE-CEA4996228DDQ28476803-6FCA638F-1E0F-4C6A-9C4A-5760C3154765Q28505268-28D7B0BF-7F19-4BCB-8267-A258675E3CB4Q28538886-B181A0CD-C44C-4FF0-BE95-AB4A22C9D171Q31131991-C5055865-EE31-4391-9EFE-BBEF75B70925Q31946843-6227A0B7-93FA-4847-A120-BC599382A620Q33284533-006D0263-8DCA-42BC-AE06-8609E3EF1159Q33597540-4F577CD2-C9FE-4FEB-9143-134A91B47099Q33602903-ADE93A03-FA68-4502-9EF9-EE08464BC457Q33605647-26BA9F3C-AB78-454A-9CAC-7953B930A7E8Q33607724-C6365758-8B76-4F3B-BA0A-E8CC46D25228Q33617127-C8600254-6602-41E3-B17C-8B9D1AE5CB2CQ33685715-EBC2AE04-3CDA-4B05-ADB8-BC08DDDB3E7BQ33696889-9A58A93F-49D4-4887-988D-9638CD9B9F2FQ33737289-309E1AA8-D98F-4893-B250-D79E7358CABBQ33750694-77763992-6AF9-4CA4-8C16-CC7E70D18331Q33752145-E0ACB9C7-401F-4B5F-A185-AAFC150AF374Q33752157-3E0FC423-B2A4-4510-8B5B-3EEEF40FF81EQ33762670-0F464A8D-DE49-4052-9187-8664CB732C64Q33891026-4FD61BA4-0875-4773-87EB-FB503FC25549Q33895266-9719DFFF-C8EC-4206-BC49-3E7554C4D217Q33943048-36C28D0E-B316-40B1-99F0-99A2D0073B39Q33998711-FC61F0BA-261F-48D5-B028-4FF11D946484Q34003756-F1CC849E-B8C3-42D8-A989-7ECD4044EFB4Q34006141-83743A8D-6803-4267-83B9-42391CA1527EQ34007433-218B8D21-05A3-4945-BD81-C53042C522A3Q34033949-DF9BCD1C-11F7-404C-A55A-866DF6F5BF6FQ34111786-89356329-0190-4939-A504-5EED75350A84Q34132796-67284580-2644-40F9-AA64-8EE051556608Q34146304-738192D2-D6B1-4840-ACF7-4CBDBED29CB3Q34157386-CD84F8DE-071E-47BA-BE96-BDC1E0EECDA3Q34527663-8FB66CC2-FFBC-49FA-A1F8-61E784303F20
P2860
Cure of murine leishmaniasis with anti-interleukin 4 monoclonal antibody. Evidence for a T cell-dependent, interferon gamma-independent mechanism.
description
1990 nî lūn-bûn
@nan
1990年の論文
@ja
1990年学术文章
@wuu
1990年学术文章
@zh-cn
1990年学术文章
@zh-hans
1990年学术文章
@zh-my
1990年学术文章
@zh-sg
1990年學術文章
@yue
1990年學術文章
@zh
1990年學術文章
@zh-hant
name
Cure of murine leishmaniasis w ...... n gamma-independent mechanism.
@ast
Cure of murine leishmaniasis w ...... n gamma-independent mechanism.
@en
type
label
Cure of murine leishmaniasis w ...... n gamma-independent mechanism.
@ast
Cure of murine leishmaniasis w ...... n gamma-independent mechanism.
@en
prefLabel
Cure of murine leishmaniasis w ...... n gamma-independent mechanism.
@ast
Cure of murine leishmaniasis w ...... n gamma-independent mechanism.
@en
P2093
P2860
P356
P1476
Cure of murine leishmaniasis w ...... n gamma-independent mechanism.
@en
P2093
B J Holaday
F P Heinzel
M D Sadick
R M Locksley
R S Dawkins
P2860
P304
P356
10.1084/JEM.171.1.115
P407
P577
1990-01-01T00:00:00Z